APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antinematode Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Antinematode Drugs Industry Research Report 2026

27 December 2025146 pages

Choose your research edition.

Industry ResearchAntinematode Drugs Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Antinematode Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Antinematode Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antinematode Drugs Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Antinematode Drugs Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Antinematode Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Antinematode Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Antinematode Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Antinematode Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Antinematode Drugs include Zhejiang Anbet Pharmaceutical Co., Ltd., Sichuan Tiande Pharmaceutical Co., Ltd., Shaoxing Minsheng Pharmaceutical Co., Ltd., Shanghai Tengrui Pharmaceutical Co., Ltd., Shanghai SPH Xinyi Pharmaceutical Co., Ltd., Shaanxi Hanwang Pharmaceutical Co., Ltd., Jiaozuo Furuitang Pharmaceutical Co., Ltd., China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. and Hubei Ruihua Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Antinematode Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Antinematode Drugs Market by Company

Zhejiang Anbet Pharmaceutical Co., Ltd.

Sichuan Tiande Pharmaceutical Co., Ltd.

Shaoxing Minsheng Pharmaceutical Co., Ltd.

Shanghai Tengrui Pharmaceutical Co., Ltd.

Shanghai SPH Xinyi Pharmaceutical Co., Ltd.

Shaanxi Hanwang Pharmaceutical Co., Ltd.

Jiaozuo Furuitang Pharmaceutical Co., Ltd.

China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd.

Hubei Ruihua Pharmaceutical Co., Ltd.

Guilin Nanyao Pharmaceutical Co., Ltd.

Fujian Dongrui Pharmaceutical Co., Ltd.

Diao Group Chengdu Pharmaceutical Co., Ltd.

Chengdu Hengda Pharmaceutical Co., Ltd.

Beijing Taiyang Pharmaceutical Co., Ltd.

Anhui Shengying Pharmaceutical Co., Ltd.

Sequent Scientific

Salius Pharma

Lasa Supergenerics Limited

K.A. Malle Pharmaceuticals

Johnson & Johnson

GlaxoSmithKline

Fredun Pharmaceuticals Ltd

Esteve Pharmaceuticals

Eipico

Cadila Pharmaceuticals

Amneal Pharmaceuticals

Antinematode Drugs Segment by Type

Albendazole

Mebendazole

Piperazine

Pyrantel Pamoate

Others

Antinematode Drugs Segment by Application

For Veterinary Use

For Human Use

Antinematode Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antinematode Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antinematode Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antinematode Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Antinematode Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Antinematode Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Antinematode Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Antinematode Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Antinematode Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Antinematode Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Antinematode Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Antinematode Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Antinematode Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Antinematode Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Antinematode Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Antinematode Drugs, Product Type & Application Table 14. Global Antinematode Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Antinematode Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Zhejiang Anbet Pharmaceutical Co., Ltd. Company Information Table 19. Zhejiang Anbet Pharmaceutical Co., Ltd. Business Overview Table 20. Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 22. Zhejiang Anbet Pharmaceutical Co., Ltd. Recent Developments Table 23. Sichuan Tiande Pharmaceutical Co., Ltd. Company Information Table 24. Sichuan Tiande Pharmaceutical Co., Ltd. Business Overview Table 25. Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 27. Sichuan Tiande Pharmaceutical Co., Ltd. Recent Developments Table 28. Shaoxing Minsheng Pharmaceutical Co., Ltd. Company Information Table 29. Shaoxing Minsheng Pharmaceutical Co., Ltd. Business Overview Table 30. Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 32. Shaoxing Minsheng Pharmaceutical Co., Ltd. Recent Developments Table 33. Shanghai Tengrui Pharmaceutical Co., Ltd. Company Information Table 34. Shanghai Tengrui Pharmaceutical Co., Ltd. Business Overview Table 35. Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 37. Shanghai Tengrui Pharmaceutical Co., Ltd. Recent Developments Table 38. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Company Information Table 39. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Business Overview Table 40. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 42. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Recent Developments Table 43. Shaanxi Hanwang Pharmaceutical Co., Ltd. Company Information Table 44. Shaanxi Hanwang Pharmaceutical Co., Ltd. Business Overview Table 45. Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 47. Shaanxi Hanwang Pharmaceutical Co., Ltd. Recent Developments Table 48. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Company Information Table 49. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Business Overview Table 50. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 52. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Recent Developments Table 53. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Company Information Table 54. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Business Overview Table 55. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 57. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Recent Developments Table 58. Hubei Ruihua Pharmaceutical Co., Ltd. Company Information Table 59. Hubei Ruihua Pharmaceutical Co., Ltd. Business Overview Table 60. Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 62. Hubei Ruihua Pharmaceutical Co., Ltd. Recent Developments Table 63. Guilin Nanyao Pharmaceutical Co., Ltd. Company Information Table 64. Guilin Nanyao Pharmaceutical Co., Ltd. Business Overview Table 65. Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 67. Guilin Nanyao Pharmaceutical Co., Ltd. Recent Developments Table 68. Fujian Dongrui Pharmaceutical Co., Ltd. Company Information Table 69. Fujian Dongrui Pharmaceutical Co., Ltd. Business Overview Table 70. Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 72. Fujian Dongrui Pharmaceutical Co., Ltd. Recent Developments Table 73. Diao Group Chengdu Pharmaceutical Co., Ltd. Company Information Table 74. Diao Group Chengdu Pharmaceutical Co., Ltd. Business Overview Table 75. Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 77. Diao Group Chengdu Pharmaceutical Co., Ltd. Recent Developments Table 78. Chengdu Hengda Pharmaceutical Co., Ltd. Company Information Table 79. Chengdu Hengda Pharmaceutical Co., Ltd. Business Overview Table 80. Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 82. Chengdu Hengda Pharmaceutical Co., Ltd. Recent Developments Table 83. Beijing Taiyang Pharmaceutical Co., Ltd. Company Information Table 84. Beijing Taiyang Pharmaceutical Co., Ltd. Business Overview Table 85. Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 87. Beijing Taiyang Pharmaceutical Co., Ltd. Recent Developments Table 88. Anhui Shengying Pharmaceutical Co., Ltd. Company Information Table 89. Anhui Shengying Pharmaceutical Co., Ltd. Business Overview Table 90. Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 92. Anhui Shengying Pharmaceutical Co., Ltd. Recent Developments Table 93. Sequent Scientific Company Information Table 94. Sequent Scientific Business Overview Table 95. Sequent Scientific Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Sequent Scientific Antinematode Drugs Product Portfolio Table 97. Sequent Scientific Recent Developments Table 98. Salius Pharma Company Information Table 99. Salius Pharma Business Overview Table 100. Salius Pharma Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Salius Pharma Antinematode Drugs Product Portfolio Table 102. Salius Pharma Recent Developments Table 103. Lasa Supergenerics Limited Company Information Table 104. Lasa Supergenerics Limited Business Overview Table 105. Lasa Supergenerics Limited Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Lasa Supergenerics Limited Antinematode Drugs Product Portfolio Table 107. Lasa Supergenerics Limited Recent Developments Table 108. K.A. Malle Pharmaceuticals Company Information Table 109. K.A. Malle Pharmaceuticals Business Overview Table 110. K.A. Malle Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. K.A. Malle Pharmaceuticals Antinematode Drugs Product Portfolio Table 112. K.A. Malle Pharmaceuticals Recent Developments Table 113. Johnson & Johnson Company Information Table 114. Johnson & Johnson Business Overview Table 115. Johnson & Johnson Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Johnson & Johnson Antinematode Drugs Product Portfolio Table 117. Johnson & Johnson Recent Developments Table 118. GlaxoSmithKline Company Information Table 119. GlaxoSmithKline Business Overview Table 120. GlaxoSmithKline Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. GlaxoSmithKline Antinematode Drugs Product Portfolio Table 122. GlaxoSmithKline Recent Developments Table 123. Fredun Pharmaceuticals Ltd Company Information Table 124. Fredun Pharmaceuticals Ltd Business Overview Table 125. Fredun Pharmaceuticals Ltd Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Fredun Pharmaceuticals Ltd Antinematode Drugs Product Portfolio Table 127. Fredun Pharmaceuticals Ltd Recent Developments Table 128. Esteve Pharmaceuticals Company Information Table 129. Esteve Pharmaceuticals Business Overview Table 130. Esteve Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Esteve Pharmaceuticals Antinematode Drugs Product Portfolio Table 132. Esteve Pharmaceuticals Recent Developments Table 133. Eipico Company Information Table 134. Eipico Business Overview Table 135. Eipico Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Eipico Antinematode Drugs Product Portfolio Table 137. Eipico Recent Developments Table 138. Cadila Pharmaceuticals Company Information Table 139. Cadila Pharmaceuticals Business Overview Table 140. Cadila Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Cadila Pharmaceuticals Antinematode Drugs Product Portfolio Table 142. Cadila Pharmaceuticals Recent Developments Table 143. Amneal Pharmaceuticals Company Information Table 144. Amneal Pharmaceuticals Business Overview Table 145. Amneal Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Amneal Pharmaceuticals Antinematode Drugs Product Portfolio Table 147. Amneal Pharmaceuticals Recent Developments Table 148. Global Antinematode Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 149. Global Antinematode Drugs Sales by Region (2021-2026) & (K Units) Table 150. Global Antinematode Drugs Sales Market Share by Region (2021-2026) Table 151. Global Antinematode Drugs Sales by Region (2027-2032) & (K Units) Table 152. Global Antinematode Drugs Sales Market Share by Region (2027-2032) Table 153. Global Antinematode Drugs Revenue by Region (2021-2026) & (US$ Million) Table 154. Global Antinematode Drugs Revenue Market Share by Region (2021-2026) Table 155. Global Antinematode Drugs Revenue by Region (2027-2032) & (US$ Million) Table 156. Global Antinematode Drugs Revenue Market Share by Region (2027-2032) Table 157. North America Antinematode Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. North America Antinematode Drugs Sales by Country (2021-2026) & (K Units) Table 159. North America Antinematode Drugs Sales by Country (2027-2032) & (K Units) Table 160. North America Antinematode Drugs Revenue by Country (2021-2026) & (US$ Million) Table 161. North America Antinematode Drugs Revenue by Country (2027-2032) & (US$ Million) Table 162. Europe Antinematode Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. Europe Antinematode Drugs Sales by Country (2021-2026) & (K Units) Table 164. Europe Antinematode Drugs Sales by Country (2027-2032) & (K Units) Table 165. Europe Antinematode Drugs Revenue by Country (2021-2026) & (US$ Million) Table 166. Europe Antinematode Drugs Revenue by Country (2027-2032) & (US$ Million) Table 167. Asia Pacific Antinematode Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 168. Asia Pacific Antinematode Drugs Sales by Country (2021-2026) & (K Units) Table 169. Asia Pacific Antinematode Drugs Sales by Country (2027-2032) & (K Units) Table 170. Asia Pacific Antinematode Drugs Revenue by Country (2021-2026) & (US$ Million) Table 171. Asia Pacific Antinematode Drugs Revenue by Country (2027-2032) & (US$ Million) Table 172. South America Antinematode Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 173. South America Antinematode Drugs Sales by Country (2021-2026) & (K Units) Table 174. South America Antinematode Drugs Sales by Country (2027-2032) & (K Units) Table 175. South America Antinematode Drugs Revenue by Country (2021-2026) & (US$ Million) Table 176. South America Antinematode Drugs Revenue by Country (2027-2032) & (US$ Million) Table 177. Middle East and Africa Antinematode Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 178. Middle East and Africa Antinematode Drugs Sales by Country (2021-2026) & (K Units) Table 179. Middle East and Africa Antinematode Drugs Sales by Country (2027-2032) & (K Units) Table 180. Middle East and Africa Antinematode Drugs Revenue by Country (2021-2026) & (US$ Million) Table 181. Middle East and Africa Antinematode Drugs Revenue by Country (2027-2032) & (US$ Million) Table 182. Global Antinematode Drugs Sales by Type (2021-2026) & (K Units) Table 183. Global Antinematode Drugs Sales by Type (2027-2032) & (K Units) Table 184. Global Antinematode Drugs Sales Market Share by Type (2021-2026) Table 185. Global Antinematode Drugs Sales Market Share by Type (2027-2032) Table 186. Global Antinematode Drugs Revenue by Type (2021-2026) & (US$ Million) Table 187. Global Antinematode Drugs Revenue by Type (2027-2032) & (US$ Million) Table 188. Global Antinematode Drugs Revenue Market Share by Type (2021-2026) Table 189. Global Antinematode Drugs Revenue Market Share by Type (2027-2032) Table 190. Global Antinematode Drugs Price by Type (2021-2026) & (US$/Unit) Table 191. Global Antinematode Drugs Price by Type (2027-2032) & (US$/Unit) Table 192. Global Antinematode Drugs Sales by Application (2021-2026) & (K Units) Table 193. Global Antinematode Drugs Sales by Application (2027-2032) & (K Units) Table 194. Global Antinematode Drugs Sales Market Share by Application (2021-2026) Table 195. Global Antinematode Drugs Sales Market Share by Application (2027-2032) Table 196. Global Antinematode Drugs Revenue by Application (2021-2026) & (US$ Million) Table 197. Global Antinematode Drugs Revenue by Application (2027-2032) & (US$ Million) Table 198. Global Antinematode Drugs Revenue Market Share by Application (2021-2026) Table 199. Global Antinematode Drugs Revenue Market Share by Application (2027-2032) Table 200. Global Antinematode Drugs Price by Application (2021-2026) & (US$/Unit) Table 201. Global Antinematode Drugs Price by Application (2027-2032) & (US$/Unit) Table 202. Key Raw Materials Table 203. Raw Materials Key Suppliers Table 204. Antinematode Drugs Distributors List Table 205. Antinematode Drugs Customers List Table 206. Antinematode Drugs Industry Trends Table 207. Antinematode Drugs Industry Drivers Table 208. Antinematode Drugs Industry Restraints Table 209. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Antinematode Drugs Product Image Figure 5. Global Antinematode Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Antinematode Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Antinematode Drugs Sales (2021-2032) & (K Units) Figure 8. Global Antinematode Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Albendazole Product Image Figure 10. Mebendazole Product Image Figure 11. Piperazine Product Image Figure 12. Pyrantel Pamoate Product Image Figure 13. Others Product Image Figure 14. For Veterinary Use Product Image Figure 15. For Human Use Product Image Figure 16. Global Antinematode Drugs Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Antinematode Drugs, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Antinematode Drugs Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Antinematode Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Antinematode Drugs Sales by Region in 2025 Figure 22. Global Antinematode Drugs Revenue by Region in 2025 Figure 23. North America Antinematode Drugs Market Size by Country in 2025 Figure 24. North America Antinematode Drugs Sales Market Share by Country (2021-2032) Figure 25. North America Antinematode Drugs Revenue Market Share by Country (2021-2032) Figure 26. United States Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Antinematode Drugs Market Size by Country in 2025 Figure 30. Europe Antinematode Drugs Sales Market Share by Country (2021-2032) Figure 31. Europe Antinematode Drugs Revenue Market Share by Country (2021-2032) Figure 32. Germany Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Antinematode Drugs Market Size by Country in 2025 Figure 43. Asia Pacific Antinematode Drugs Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Antinematode Drugs Revenue Market Share by Country (2021-2032) Figure 45. China Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Antinematode Drugs Market Size by Country in 2025 Figure 54. South America Antinematode Drugs Sales Market Share by Country (2021-2032) Figure 55. South America Antinematode Drugs Revenue Market Share by Country (2021-2032) Figure 56. Brazil Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Antinematode Drugs Market Size by Country in 2025 Figure 60. Middle East and Africa Antinematode Drugs Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Antinematode Drugs Revenue Market Share by Country (2021-2032) Figure 62. Egypt Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Antinematode Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Antinematode Drugs Sales Market Share by Type (2021-2032) Figure 68. Global Antinematode Drugs Revenue Market Share by Type (2021-2032) Figure 69. Global Antinematode Drugs Price (US$/Unit) by Type (2021-2032) Figure 70. Global Antinematode Drugs Sales Market Share by Application (2021-2032) Figure 71. Global Antinematode Drugs Revenue Market Share by Application (2021-2032) Figure 72. Global Antinematode Drugs Price (US$/Unit) by Application (2021-2032) Figure 73. Antinematode Drugs Value Chain Figure 74. Antinematode Drugs Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Antinematode Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Albendazole
  • Mebendazole
  • Piperazine
  • Pyrantel Pamoate
  • Others
Applications
  • For Veterinary Use
  • For Human Use
Companies covered
  • Zhejiang Anbet Pharmaceutical Co., Ltd.
  • Sichuan Tiande Pharmaceutical Co., Ltd.
  • Shaoxing Minsheng Pharmaceutical Co., Ltd.
  • Shanghai Tengrui Pharmaceutical Co., Ltd.
  • Shanghai SPH Xinyi Pharmaceutical Co., Ltd.
  • Shaanxi Hanwang Pharmaceutical Co., Ltd.
  • Jiaozuo Furuitang Pharmaceutical Co., Ltd.
  • China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd.
  • Hubei Ruihua Pharmaceutical Co., Ltd.
  • Guilin Nanyao Pharmaceutical Co., Ltd.
  • Fujian Dongrui Pharmaceutical Co., Ltd.
  • Diao Group Chengdu Pharmaceutical Co., Ltd.
  • Chengdu Hengda Pharmaceutical Co., Ltd.
  • Beijing Taiyang Pharmaceutical Co., Ltd.
  • Anhui Shengying Pharmaceutical Co., Ltd.
  • Sequent Scientific
  • Salius Pharma
  • Lasa Supergenerics Limited
  • K.A. Malle Pharmaceuticals
  • Johnson & Johnson
  • GlaxoSmithKline
  • Fredun Pharmaceuticals Ltd
  • Esteve Pharmaceuticals
  • Eipico
  • Cadila Pharmaceuticals
  • Amneal Pharmaceuticals

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Antinematode Drugs Market Size (2021-2032)
  4. 2.2.2 Global Antinematode Drugs Sales (2021-2032)
  5. 2.2.3 Global Antinematode Drugs Market Average Price (2021-2032)
  6. 2.3 Antinematode Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Albendazole
  9. 2.3.3 Mebendazole
  10. 2.3.4 Piperazine
  11. 2.3.5 Pyrantel Pamoate
  12. 2.3.6 Others
  13. 2.4 Antinematode Drugs by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 For Veterinary Use
  16. 2.4.3 For Human Use
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Antinematode Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Antinematode Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Antinematode Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Antinematode Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Antinematode Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Antinematode Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Antinematode Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Antinematode Drugs, Established Date
  9. 3.9 Global Antinematode Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Zhejiang Anbet Pharmaceutical Co., Ltd.
  2. 4.1.1 Zhejiang Anbet Pharmaceutical Co., Ltd. Company Information
  3. 4.1.2 Zhejiang Anbet Pharmaceutical Co., Ltd. Business Overview
  4. 4.1.3 Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  6. 4.1.5 Zhejiang Anbet Pharmaceutical Co., Ltd. Recent Developments
  7. 4.2 Sichuan Tiande Pharmaceutical Co., Ltd.
  8. 4.2.1 Sichuan Tiande Pharmaceutical Co., Ltd. Company Information
  9. 4.2.2 Sichuan Tiande Pharmaceutical Co., Ltd. Business Overview
  10. 4.2.3 Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  12. 4.2.5 Sichuan Tiande Pharmaceutical Co., Ltd. Recent Developments
  13. 4.3 Shaoxing Minsheng Pharmaceutical Co., Ltd.
  14. 4.3.1 Shaoxing Minsheng Pharmaceutical Co., Ltd. Company Information
  15. 4.3.2 Shaoxing Minsheng Pharmaceutical Co., Ltd. Business Overview
  16. 4.3.3 Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  18. 4.3.5 Shaoxing Minsheng Pharmaceutical Co., Ltd. Recent Developments
  19. 4.4 Shanghai Tengrui Pharmaceutical Co., Ltd.
  20. 4.4.1 Shanghai Tengrui Pharmaceutical Co., Ltd. Company Information
  21. 4.4.2 Shanghai Tengrui Pharmaceutical Co., Ltd. Business Overview
  22. 4.4.3 Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  24. 4.4.5 Shanghai Tengrui Pharmaceutical Co., Ltd. Recent Developments
  25. 4.5 Shanghai SPH Xinyi Pharmaceutical Co., Ltd.
  26. 4.5.1 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Company Information
  27. 4.5.2 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Business Overview
  28. 4.5.3 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  30. 4.5.5 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Recent Developments
  31. 4.6 Shaanxi Hanwang Pharmaceutical Co., Ltd.
  32. 4.6.1 Shaanxi Hanwang Pharmaceutical Co., Ltd. Company Information
  33. 4.6.2 Shaanxi Hanwang Pharmaceutical Co., Ltd. Business Overview
  34. 4.6.3 Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  36. 4.6.5 Shaanxi Hanwang Pharmaceutical Co., Ltd. Recent Developments
  37. 4.7 Jiaozuo Furuitang Pharmaceutical Co., Ltd.
  38. 4.7.1 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Company Information
  39. 4.7.2 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Business Overview
  40. 4.7.3 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  42. 4.7.5 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Recent Developments
  43. 4.8 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd.
  44. 4.8.1 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Company Information
  45. 4.8.2 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Business Overview
  46. 4.8.3 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  48. 4.8.5 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Recent Developments
  49. 4.9 Hubei Ruihua Pharmaceutical Co., Ltd.
  50. 4.9.1 Hubei Ruihua Pharmaceutical Co., Ltd. Company Information
  51. 4.9.2 Hubei Ruihua Pharmaceutical Co., Ltd. Business Overview
  52. 4.9.3 Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  54. 4.9.5 Hubei Ruihua Pharmaceutical Co., Ltd. Recent Developments
  55. 4.10 Guilin Nanyao Pharmaceutical Co., Ltd.
  56. 4.10.1 Guilin Nanyao Pharmaceutical Co., Ltd. Company Information
  57. 4.10.2 Guilin Nanyao Pharmaceutical Co., Ltd. Business Overview
  58. 4.10.3 Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  60. 4.10.5 Guilin Nanyao Pharmaceutical Co., Ltd. Recent Developments
  61. 4.11 Fujian Dongrui Pharmaceutical Co., Ltd.
  62. 4.11.1 Fujian Dongrui Pharmaceutical Co., Ltd. Company Information
  63. 4.11.2 Fujian Dongrui Pharmaceutical Co., Ltd. Business Overview
  64. 4.11.3 Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  66. 4.11.5 Fujian Dongrui Pharmaceutical Co., Ltd. Recent Developments
  67. 4.12 Diao Group Chengdu Pharmaceutical Co., Ltd.
  68. 4.12.1 Diao Group Chengdu Pharmaceutical Co., Ltd. Company Information
  69. 4.12.2 Diao Group Chengdu Pharmaceutical Co., Ltd. Business Overview
  70. 4.12.3 Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  72. 4.12.5 Diao Group Chengdu Pharmaceutical Co., Ltd. Recent Developments
  73. 4.13 Chengdu Hengda Pharmaceutical Co., Ltd.
  74. 4.13.1 Chengdu Hengda Pharmaceutical Co., Ltd. Company Information
  75. 4.13.2 Chengdu Hengda Pharmaceutical Co., Ltd. Business Overview
  76. 4.13.3 Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  78. 4.13.5 Chengdu Hengda Pharmaceutical Co., Ltd. Recent Developments
  79. 4.14 Beijing Taiyang Pharmaceutical Co., Ltd.
  80. 4.14.1 Beijing Taiyang Pharmaceutical Co., Ltd. Company Information
  81. 4.14.2 Beijing Taiyang Pharmaceutical Co., Ltd. Business Overview
  82. 4.14.3 Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  84. 4.14.5 Beijing Taiyang Pharmaceutical Co., Ltd. Recent Developments
  85. 4.15 Anhui Shengying Pharmaceutical Co., Ltd.
  86. 4.15.1 Anhui Shengying Pharmaceutical Co., Ltd. Company Information
  87. 4.15.2 Anhui Shengying Pharmaceutical Co., Ltd. Business Overview
  88. 4.15.3 Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  90. 4.15.5 Anhui Shengying Pharmaceutical Co., Ltd. Recent Developments
  91. 4.16 Sequent Scientific
  92. 4.16.1 Sequent Scientific Company Information
  93. 4.16.2 Sequent Scientific Business Overview
  94. 4.16.3 Sequent Scientific Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Sequent Scientific Antinematode Drugs Product Portfolio
  96. 4.16.5 Sequent Scientific Recent Developments
  97. 4.17 Salius Pharma
  98. 4.17.1 Salius Pharma Company Information
  99. 4.17.2 Salius Pharma Business Overview
  100. 4.17.3 Salius Pharma Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Salius Pharma Antinematode Drugs Product Portfolio
  102. 4.17.5 Salius Pharma Recent Developments
  103. 4.18 Lasa Supergenerics Limited
  104. 4.18.1 Lasa Supergenerics Limited Company Information
  105. 4.18.2 Lasa Supergenerics Limited Business Overview
  106. 4.18.3 Lasa Supergenerics Limited Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Lasa Supergenerics Limited Antinematode Drugs Product Portfolio
  108. 4.18.5 Lasa Supergenerics Limited Recent Developments
  109. 4.19 K.A. Malle Pharmaceuticals
  110. 4.19.1 K.A. Malle Pharmaceuticals Company Information
  111. 4.19.2 K.A. Malle Pharmaceuticals Business Overview
  112. 4.19.3 K.A. Malle Pharmaceuticals Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 K.A. Malle Pharmaceuticals Antinematode Drugs Product Portfolio
  114. 4.19.5 K.A. Malle Pharmaceuticals Recent Developments
  115. 4.20 Johnson & Johnson
  116. 4.20.1 Johnson & Johnson Company Information
  117. 4.20.2 Johnson & Johnson Business Overview
  118. 4.20.3 Johnson & Johnson Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Johnson & Johnson Antinematode Drugs Product Portfolio
  120. 4.20.5 Johnson & Johnson Recent Developments
  121. 4.21 GlaxoSmithKline
  122. 4.21.1 GlaxoSmithKline Company Information
  123. 4.21.2 GlaxoSmithKline Business Overview
  124. 4.21.3 GlaxoSmithKline Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 GlaxoSmithKline Antinematode Drugs Product Portfolio
  126. 4.21.5 GlaxoSmithKline Recent Developments
  127. 4.22 Fredun Pharmaceuticals Ltd
  128. 4.22.1 Fredun Pharmaceuticals Ltd Company Information
  129. 4.22.2 Fredun Pharmaceuticals Ltd Business Overview
  130. 4.22.3 Fredun Pharmaceuticals Ltd Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Fredun Pharmaceuticals Ltd Antinematode Drugs Product Portfolio
  132. 4.22.5 Fredun Pharmaceuticals Ltd Recent Developments
  133. 4.23 Esteve Pharmaceuticals
  134. 4.23.1 Esteve Pharmaceuticals Company Information
  135. 4.23.2 Esteve Pharmaceuticals Business Overview
  136. 4.23.3 Esteve Pharmaceuticals Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Esteve Pharmaceuticals Antinematode Drugs Product Portfolio
  138. 4.23.5 Esteve Pharmaceuticals Recent Developments
  139. 4.24 Eipico
  140. 4.24.1 Eipico Company Information
  141. 4.24.2 Eipico Business Overview
  142. 4.24.3 Eipico Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Eipico Antinematode Drugs Product Portfolio
  144. 4.24.5 Eipico Recent Developments
  145. 4.25 Cadila Pharmaceuticals
  146. 4.25.1 Cadila Pharmaceuticals Company Information
  147. 4.25.2 Cadila Pharmaceuticals Business Overview
  148. 4.25.3 Cadila Pharmaceuticals Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  149. 4.25.4 Cadila Pharmaceuticals Antinematode Drugs Product Portfolio
  150. 4.25.5 Cadila Pharmaceuticals Recent Developments
  151. 4.26 Amneal Pharmaceuticals
  152. 4.26.1 Amneal Pharmaceuticals Company Information
  153. 4.26.2 Amneal Pharmaceuticals Business Overview
  154. 4.26.3 Amneal Pharmaceuticals Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  155. 4.26.4 Amneal Pharmaceuticals Antinematode Drugs Product Portfolio
  156. 4.26.5 Amneal Pharmaceuticals Recent Developments
5 Global Antinematode Drugs Market Scenario by Region
  1. 5.1 Global Antinematode Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Antinematode Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Antinematode Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Antinematode Drugs Sales by Region: 2027-2032
  5. 5.3 Global Antinematode Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Antinematode Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Antinematode Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Antinematode Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Antinematode Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Antinematode Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Antinematode Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Antinematode Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Antinematode Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Antinematode Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Antinematode Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Antinematode Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Antinematode Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Antinematode Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Antinematode Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Antinematode Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Antinematode Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Antinematode Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Antinematode Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Antinematode Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Antinematode Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Antinematode Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Antinematode Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Antinematode Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Antinematode Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Antinematode Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Antinematode Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Antinematode Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Antinematode Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Antinematode Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Antinematode Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Antinematode Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Antinematode Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Antinematode Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Antinematode Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Antinematode Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Antinematode Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Antinematode Drugs Value Chain Analysis
  2. 8.1.1 Antinematode Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Antinematode Drugs Production Mode & Process
  5. 8.2 Antinematode Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Antinematode Drugs Distributors
  8. 8.2.3 Antinematode Drugs Customers
9 Global Antinematode Drugs Analyzing Market Dynamics
  1. 9.1 Antinematode Drugs Industry Trends
  2. 9.2 Antinematode Drugs Industry Drivers
  3. 9.3 Antinematode Drugs Industry Opportunities and Challenges
  4. 9.4 Antinematode Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst